title: Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice.
abstract: IL-6 (interleukin 6) plays an important role in the development and growth of hepatocellular carcinoma (HCC) via both classic signaling and trans-signaling pathways. Soluble gp130 (sgp130) is known to be a natural inhibitor of the trans-signaling pathway. In the present study, our goal was to investigate whether recombinant sgp130 could suppress the initiation and progression of HCC in mouse models. Our results demonstrate that sgp130 induced an apoptosis of HepG2 cells and inhibited the clonogenicity of HepG2 in vitro. Moreover, the IL-6 trans-signaling pathway is significantly suppressed by sgp130 as reflected by the decrease in the level of STAT3 phosphorylation and other inflammatory factors both in vitro and in vivo. In the DEN-induced HCC mouse model, intravenous injection of sgp130 attenuated hepatic fibrosis at 16 weeks and reduced the initiation and progression of primary HCC at 36 weeks. Furthermore, our results also demonstrate that intravenous administration of sgp130 significantly suppressed the growth and metastasis of xenograft human HCC in NOD/SCID mice.
authors.affiliation: Institute of Pharmaceutical Biotechnology and Engineering, College of Biological Science and Biotechnology, Fuzhou University, Fuzhou, Fujian, 350002, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Hong
authors.affiliation: Institute of Pharmaceutical Biotechnology and Engineering, College of Biological Science and Biotechnology, Fuzhou University, Fuzhou, Fujian, 350002, China.
authors.forename: Hang
authors.initials: H
authors.lastname: Wang
authors.affiliation: Institute of Pharmaceutical Biotechnology and Engineering, College of Biological Science and Biotechnology, Fuzhou University, Fuzhou, Fujian, 350002, China.
authors.forename: Guoying
authors.initials: G
authors.lastname: Shen
authors.affiliation: Institute of Pharmaceutical Biotechnology and Engineering, College of Biological Science and Biotechnology, Fuzhou University, Fuzhou, Fujian, 350002, China.
authors.forename: Da
authors.initials: D
authors.lastname: Lin
authors.affiliation: Institute of Pharmaceutical Biotechnology and Engineering, College of Biological Science and Biotechnology, Fuzhou University, Fuzhou, Fujian, 350002, China.
authors.forename: Yanxue
authors.initials: Y
authors.lastname: Lin
authors.affiliation: Institute of Pharmaceutical Biotechnology and Engineering, College of Biological Science and Biotechnology, Fuzhou University, Fuzhou, Fujian, 350002, China.
authors.forename: Nanhui
authors.initials: N
authors.lastname: Ye
authors.affiliation: Institute of Pharmaceutical Biotechnology and Engineering, College of Biological Science and Biotechnology, Fuzhou University, Fuzhou, Fujian, 350002, China.
authors.forename: Yashan
authors.initials: Y
authors.lastname: Guo
authors.affiliation: Institute of Pharmaceutical Biotechnology and Engineering, College of Biological Science and Biotechnology, Fuzhou University, Fuzhou, Fujian, 350002, China.
authors.forename: Qiaoling
authors.initials: Q
authors.lastname: Li
authors.affiliation: Institute of Pharmaceutical Biotechnology and Engineering, College of Biological Science and Biotechnology, Fuzhou University, Fuzhou, Fujian, 350002, China.
authors.forename: Nanhui
authors.initials: N
authors.lastname: Ye
authors.affiliation: Institute of Pharmaceutical Biotechnology and Engineering, College of Biological Science and Biotechnology, Fuzhou University, Fuzhou, Fujian, 350002, China.
authors.forename: Chengjun
authors.initials: C
authors.lastname: Deng
authors.affiliation: Institute of Pharmaceutical Biotechnology and Engineering, College of Biological Science and Biotechnology, Fuzhou University, Fuzhou, Fujian, 350002, China.
authors.forename: Chun
authors.initials: C
authors.lastname: Meng
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002273:Carcinogens; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism* / Q000473:pathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D050822:Cytokine Receptor gp130 / Q000378:metabolism*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D008113:Liver Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D011994:Recombinant Proteins / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects; D047368:Tumor Burden; D023041:Xenograft Model Antitumor Assays
chemical_list: D002273:Carcinogens; D015850:Interleukin-6; D011994:Recombinant Proteins; D050822:Cytokine Receptor gp130